Previous studies show a direct association between development of type 2 diabetes and worsening of brain health. Now, researchers from Iowa State University discovered new biomarkers to predict type 2 diabetes (T2D) and Alzheimer's disease. Researchers found that autotaxin (an enzyme in the brain) is very effective in predicting type 2 diabetes and Alzheimer's disease.
Researchers analyzed data such as autotaxin levels, memory levels and diabetes in 287 individuals aged 56 to 89 years. In case of a relationship between memory and autotaxin levels, one point increase in autotaxin levels translates into memory decrease of 3.5 to 5 percent. In case of a relationship between diabetes and autotaxin levels, one point increase in autotaxin levels translates into 300 percent increase in development of pre-diabetes or diabetes.
Researchers say autotaxin is a better biomarker in predicting Alzheimer's disease compared with other biomarkers. Researchers say as triglyceride levels increases, autotaxin levels also increase in an individual. Researchers are hoping that patients can get treatment and prevent worse Alzheimer's and diabetes disease situation with the early autotaxin biomarker indicator.
The study was done by Assistant Prof Auriel Willette and by Kelsey McLimans, a graduate research assistant. The study findings were published in the Journal of Alzheimer's Disease.
Xultophy drug made by Novo Nordisk has been approved by United States FDA based on the results of DUAL and subsequent clinical trials. Few facts about this drug are
The drug is expected in the United States market during the first half of 2017. Dr. John Buse from the University of North Carolina School of Medicine, Chapel Hill was the principal investigator of DUAL II trial.
A study done by scientists from Federal University of Rio de Janeiro (UFRJ) shows a way to prevent heart arrhythmias disease due to high blood sugar levels. Scientists say high blood sugar levels cause inflammation and inflammation cause the production of IL-1-beta (also known as leukocytic pyrogen). IL-1-beta leads to arrhythmias condition in the heart.
Scientists say there are two drugs which can block the production of IL-1-beta and prevent heart changes. They are
Experiments with mice models were successful. Prof Medai says the study results are very encouraging to treat heart disease caused due to diabetes. This study was coordinated by Prof Emiliano Medei and the study findings were published in the Nature Communications.
A study done by researchers shows lifetime risk with cardiovascular disease can be reduced by 90 percent with the combination of lower levels of LDL cholesterol and lower levels of systolic blood pressure. Risks with LDL cholesterol and systolic blood pressure to cardiovascular disease are independent, multiplicative and cumulative. Researchers studied cardiovascular risks associated with genetic risk factors of 102,773 individuals with the outcome of diseases such as
Dr. Brian Ference says the cardiovascular disease can be preventable if an individual achieves lower LDL levels and lower systolic blood pressure. Researchers need to focus on studies to find who gets most of the benefits with an early intervention. Lifestyle changes can improve cholesterol and blood pressure levels in an individual and helps in reducing cardiovascular diseases. Lead investigator of the study is Dr. Brian Ference.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.